Next Article in Journal
Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country
Previous Article in Journal
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
 
 
Systematic Review

In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients

1
Médecine Interne, Hôpital Louis Mourier, Assistance Publique Hôpitaux de Paris, 92700 Colombes, France
2
Université de Paris Cité, 75006 Paris, France
3
Unité Inserm UMR-S1140 Innovation Thérapeutique en Hémostase, 75006 Paris, France
4
INNOVTE-FCRIN, CEDEX 2, 42055 Saint-Etienne, France
*
Author to whom correspondence should be addressed.
Academic Editor: Jeroen T. Buijs
Cancers 2022, 14(8), 1937; https://doi.org/10.3390/cancers14081937
Received: 10 March 2022 / Revised: 4 April 2022 / Accepted: 8 April 2022 / Published: 12 April 2022
(This article belongs to the Special Issue Venous Thromboembolism and Cancer)
Patients with venous thromboembolism events in the context of cancer should receive anticoagulants as long as the cancer is active. Therefore, a tailor-made anticoagulation strategy should rely on an individualized assessment of the risks of recurrent venous thromboembolism and anticoagulant-associated bleeding. No existing risk assessment model for anticoagulant-associated bleeding risk has been validated for cancer-associated thrombosis. To obtain a better risk assessment model to assess anticoagulant-associated bleeding risk in cancer-associated thrombosis patients, we deemed it necessary to answer questions related to how and when to assess anticoagulant-associated bleeding risk as well as what factors to assess for which patients.
Patients with venous thromboembolism events (VTE) in the context of cancer should receive anticoagulants as long as the cancer is active. Therefore, a tailor-made anticoagulation strategy should rely on an individualized risk assessment model (RAM) of recurrent VTE and anticoagulant-associated bleeding. The aim of this review is to investigate the applicability of the currently available RAMs for anticoagulant-associated bleeding after VTE in the CAT population and to provide new insights on how we can succeed in developing a new anticoagulant-associated bleeding RAM for the current medical care of CAT patients. A systematic search for peer-reviewed publications was performed in PubMed. Studies, including systematic reviews, were eligible if they comprised patients with VTE and used a design for developing a prediction model, score, or other prognostic tools for anticoagulant-associated bleeding during anticoagulant treatment. Out of 15 RAMs, just the CAT-BLEED was developed for CAT patients and none of the presented RAMs developed for the VTE general population were externally validated in a population of CAT patients. The current review illustrates the limitations of the available RAMs for anticoagulant-associated bleeding in CAT patients. The development of a RAM for bleeding risk assessment in patients with CAT is warranted. View Full-Text
Keywords: cancer associated thrombosis; bleeding; risk assessment model cancer associated thrombosis; bleeding; risk assessment model
Show Figures

Graphical abstract

MDPI and ACS Style

Poénou, G.; Tolédano, E.; Helfer, H.; Plaisance, L.; Happe, F.; Versini, E.; Diab, N.; Djennaoui, S.; Mahé, I. In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients. Cancers 2022, 14, 1937. https://doi.org/10.3390/cancers14081937

AMA Style

Poénou G, Tolédano E, Helfer H, Plaisance L, Happe F, Versini E, Diab N, Djennaoui S, Mahé I. In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients. Cancers. 2022; 14(8):1937. https://doi.org/10.3390/cancers14081937

Chicago/Turabian Style

Poénou, Géraldine, Emmanuel Tolédano, Hélène Helfer, Ludovic Plaisance, Florent Happe, Edouard Versini, Nevine Diab, Sadji Djennaoui, and Isabelle Mahé. 2022. "In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients" Cancers 14, no. 8: 1937. https://doi.org/10.3390/cancers14081937

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop